Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Test and Treat Strategy for Hepatitis C in Cairns
NCT05264558Phase 4Completed
- Sponsor
- Burnet Institute
- Start
- Jul 2022
- Primary completion
- Aug 2023
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of velpatasvir in hepatitis C (HCV), sponsored by Burnet Institute. Started Jul 2022; status: completed.
02
Drugs
velpatasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT05264558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05264558.